Rosetta Genomics said this week that it has received notice that the US Patent and Trademark Office will allow claims in a patent application related to microRNA-378 as a specific miRNA sequence, as well as sequence variants.

“The allowed claims are directed to novel technologies that can be used for detecting and profiling microRNAs, and have application in the use of microRNA-378 as diagnostic biomarkers and therapeutics targets,” the company said, noting that the miRNA is a key part of its MiRview Mets line of cancer diagnostics.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.